Secretome Therapeutics: Pioneering nCPC-Based Cardiovascular Therapies
  • Home
  • Pipeline
  • Leadership
  • News & Publications
    • News
    • Publications
Select Page

Secretome Therapeutics Appoints Margot Connor as Board Director and Assembles World-Class Clinical Advisory Board

by secretome | Jul 18, 2023 | News

DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “Margot’s unparalleled...

Secretome Therapeutics Presents Scientific Poster on the Essential Role of Complete Secretome in Regenerative Cell Therapy at ISSCR 2023 Annual Meeting

by secretome | May 16, 2023 | Investors, News

[DALLAS, TX – May 12, 2023] — Secretome Therapeutics, a pioneering biotechnology company focused on developing regenerative cell therapies, is pleased to announce its participation in the prestigious ISSCR 2023 Annual Meeting, held at the Boston Convention and...
Next Entries »

Recent Posts

  • Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction
  • Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
  • Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
  • Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
  • Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21
© 2025 Secretome Therapeutics | Brady UX